VIVA BIOTECH (01873) Divests Stake in an Investment Incubator Company

Stock News12-14 19:22

VIVA BIOTECH (01873) announced that Arthrosi Therapeutics has informed the company that on December 13, 2025, the buyer, Sobi US Holding Corp., agreed to acquire Arthrosi Therapeutics through a merger. Following the completion of the transaction, the company will no longer hold any equity in Arthrosi Therapeutics. The merger agreement stipulates an upfront payment of $950 million (subject to customary adjustments) and contingent consideration of up to $550 million.

Arthrosi Therapeutics is a Delaware-based clinical-stage biotech company focused on developing pozdeutinurad, a potential best-in-class, highly efficient, and selective next-generation URAT1 inhibitor designed to reduce serum uric acid levels, minimize acute flares, and decrease tophi in progressive gout patients.

As of the announcement date, VIVA BIOTECH's incubator held approximately 3.14% of Arthrosi Therapeutics' equity (on a fully diluted and converted basis). The board believes the merger allows the group to realize the long-term accumulated investment value in Arthrosi Therapeutics and presents an opportunity to enhance the group's financial flexibility.

Proceeds from the merger will be used to supplement the group's working capital and support the growth and development of other investment and incubation businesses.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166210762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-14 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166210762","market":"hk","top_or_hot":-1,"title":"VIVA BIOTECH (01873) Divests Stake in an Investment Incubator Company","media":"Stock News","content":"<p>VIVA BIOTECH (01873) announced that Arthrosi Therapeutics has informed the company that on December 13, 2025, the buyer, Sobi US Holding Corp., agreed to acquire Arthrosi Therapeutics through a merger. Following the completion of the transaction, the company will no longer hold any equity in Arthrosi Therapeutics. The merger agreement stipulates an upfront payment of $950 million (subject to customary adjustments) and contingent consideration of up to $550 million.</p>\n<p>Arthrosi Therapeutics is a Delaware-based clinical-stage biotech company focused on developing pozdeutinurad, a potential best-in-class, highly efficient, and selective next-generation URAT1 inhibitor designed to reduce serum uric acid levels, minimize acute flares, and decrease tophi in progressive gout patients.</p>\n<p>As of the announcement date, VIVA BIOTECH's incubator held approximately 3.14% of Arthrosi Therapeutics' equity (on a fully diluted and converted basis). The board believes the merger allows the group to realize the long-term accumulated investment value in Arthrosi Therapeutics and presents an opportunity to enhance the group's financial flexibility.</p>\n<p>Proceeds from the merger will be used to supplement the group's working capital and support the growth and development of other investment and incubation businesses.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VIVA BIOTECH (01873) Divests Stake in an Investment Incubator Company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVIVA BIOTECH (01873) Divests Stake in an Investment Incubator Company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-14 19:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VIVA BIOTECH (01873) announced that Arthrosi Therapeutics has informed the company that on December 13, 2025, the buyer, Sobi US Holding Corp., agreed to acquire Arthrosi Therapeutics through a merger. Following the completion of the transaction, the company will no longer hold any equity in Arthrosi Therapeutics. The merger agreement stipulates an upfront payment of $950 million (subject to customary adjustments) and contingent consideration of up to $550 million.</p>\n<p>Arthrosi Therapeutics is a Delaware-based clinical-stage biotech company focused on developing pozdeutinurad, a potential best-in-class, highly efficient, and selective next-generation URAT1 inhibitor designed to reduce serum uric acid levels, minimize acute flares, and decrease tophi in progressive gout patients.</p>\n<p>As of the announcement date, VIVA BIOTECH's incubator held approximately 3.14% of Arthrosi Therapeutics' equity (on a fully diluted and converted basis). The board believes the merger allows the group to realize the long-term accumulated investment value in Arthrosi Therapeutics and presents an opportunity to enhance the group's financial flexibility.</p>\n<p>Proceeds from the merger will be used to supplement the group's working capital and support the growth and development of other investment and incubation businesses.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"","article_id":"1166210762","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166210762","pubTimestamp":1765711334,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VIVA BIOTECH (01873) announced that Arthrosi Therapeutics has informed the company that on December 13, 2025, the buyer, Sobi US Holding Corp., agreed to acquire Arthrosi Therapeutics through a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1141":"生命科学工具和服务","01873":"维亚生物","BK1576":"医药外包概念"},"translate_title":"维亚生物(01873)剥离投资孵化器公司股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"VIVA BIOTECH (01873) announced that Arthrosi Therapeutics has informed the company that on December 13, 2025, the buyer, Sobi US Holding Corp., agreed to acquire Arthrosi Therapeutics through a merger. Following the completion of the transaction, the company will no longer hold any equity in Arthrosi Therapeutics. The merger agreement stipulates an upfront payment of $950 million (subject to customary adjustments) and contingent consideration of up to $550 million.\nArthrosi Therapeutics is a Delaware-based clinical-stage biotech company focused on developing pozdeutinurad, a potential best-in-class, highly efficient, and selective next-generation URAT1 inhibitor designed to reduce serum uric acid levels, minimize acute flares, and decrease tophi in progressive gout patients.\nAs of the announcement date, VIVA BIOTECH's incubator held approximately 3.14% of Arthrosi Therapeutics' equity (on a fully diluted and converted basis). The board believes the merger allows the group to realize the long-term accumulated investment value in Arthrosi Therapeutics and presents an opportunity to enhance the group's financial flexibility.\nProceeds from the merger will be used to supplement the group's working capital and support the growth and development of other investment and incubation businesses.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166210762","isCrawlerRequest":true}